Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Office Director Memo: Indication Statement - Provenge, April 29, 2010


From:  Celia M.Witten, Ph.D., M.D., Office Director FDA/CBER/OCTGT
To:  BLA/STN# 125197/0 Sipuleucel-T/Provenge® BLA file
Date:  April 29, 2010
Subject:  Office Director Memo:  Indication Statement

Sipuleucel-T (Provenge) is being licensed for the following indication:
PROVENGE is indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  
This indication reflects the population studied.  The product is novel and it is not known if the study results are generalizable to a broader population with more advanced disease.  As noted in the clinical reviewers’ memo, pain is a prognostic factor for survival for castrate resistant (hormone refractory) patients and the amount of residual disease could affect the impact of this therapy since Sipuleucel-T is designed to work by an immunological effect.

Page Last Updated: 06/02/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English